:: Volume 13, Issue 1 (Winter 2022) ::
Caspian J Intern Med 2022, 13(1): 1-9 Back to browse issues page
Role of Frizzled receptor expression on patients’ survival with gastrointestinal cancers: A systematic review with meta-analysis
Nasim Hafezi , Reza Alizadeh-Navaei , Monireh Golpour , Parisa Zafari , Abolghasem Ajami *
Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran , ajami36@gmail.com
Abstract:   (1622 Views)
Background: Frizzled receptors (FZD) play a pivotal role in the initiation and progression of a wide array of cancers. Dysregulated expression of FZD receptors is correlated with higher metastasis and invasive potential, as well as short survival in many malignancies. In this meta-analysis, we aimed to verify the prognostic value of FZD receptor expression on patients’ survival with different types of gastrointestinal (GI) cancers, including gastric, colorectal, and esophageal cancers.
Methods: A systematic search was performed using PubMed, Scopus, and Web of Science from 2000 to November 2020. Fourteen studies, including 2997 patients met our inclusion criteria, in which nine articles were considered FZD7 while the rest were about other FZD members. The fixed-effect model was used to estimate the pooled hazard ratio (HR) and the 5-year overall survival (OS) rate. We used the Newcastle-Ottawa scale of cohort articles to determine the quality of included studies.
Results: The results showed that high expression of FZD receptors is associated with the poor survival in patients with GI cancers (HR= 1.83, 95% CI: 1.5–2.17). Moreover, multivariate analysis indicated that FZD receptors could be considered as an independent prognostic factor (HR = 1.76, 95% CI: 1.37–2.16).
Conclusion: According to our results, overexpression of FZD receptors predicts a poor prognosis in patients with GI cancers and could be used as a useful therapeutic target.
Keywords: Frizzled receptor, expression gastrointestinal cancer, survival
Full-Text [PDF 427 kb]   (439 Downloads)    
Type of Study: Review Article | Subject: Oncology
Received: 2021/02/23 | Accepted: 2021/07/3 | Published: 2022/01/20

XML     Print

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 13, Issue 1 (Winter 2022) Back to browse issues page